Speak to our team of experts about your research and how our leading portfolio of hepatic products and research services can help you accelerate your R&D programs, gain regulatory approval, and achieve your commercial objectives. Visit BioIVT at booth # 3804.
Exhibitor Hosted Session
What is the Metformin Clinical DDI Study Design that Enables An Efficacy- and Safety-Based Dose Adjustment Decision?
March 12, 2019 | 12:00-1:00 PM
CC Room 339
Speaker: Dr. Maciej Zamek-Gliszcynski, GSK
March 11, 2019 | 9:15 am – 4: 30 pm
CC Exhibit Hall
P305: Demonstration of Hepatocyte-Targeted siRNA Transfection and Gene Silencing in the Micro-Patterned Hepatocyte Co-Culture System (HEPATOPAC®)
Using a commercially-available, non-liposomal transfection reagent that targets hepatocytes we specifically delivered small-interfering RNAs (siRNA) into the hepatocytes in the HEPATOPAC® co-cultures.
Authors: Miranda Yang, Onyi Irrechukwu, and Jeannemarie Gaffney
Author Affiliation: BioIVT
We are proud to announce the launch of the XPRESSWAY® Profile Safety Package at SOT 2019.
Understanding the safety risks associated with drug targets is essential for understanding whether undesired side effects may derail a drug discovery & development program. Therefore, knowledge of where your target of interest is expressed across human tissue and organ systems supports both the validation of that target as relevant for a particular therapeutic approach and provides information as to where unexpected or undesired expression may be.
BioIVT’s XPRESSWAY® Profile Safety Package provides this data for 46 drug targets that are known to be associated with drug safety issues. For more information, click here.